Neutrophil-lymphoycyte-ratio, platelet-lymphocyte-ratio and procalcitonin for early assessment of prognosis in patients undergoing VA-ECMO

Sci Rep. 2022 Jan 11;12(1):542. doi: 10.1038/s41598-021-04519-7.

Abstract

The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasing, but mortality remains high. Early assessment of prognosis is challenging and valid markers are lacking. This study aimed to investigate Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte-Ratio (PLR) and Procalcitonin (PCT) for early assessment of prognosis in patients undergoing VA-ECMO. This retrospective single-center cohort study included 344 consecutive patients ≥ 18 years who underwent VA-ECMO due to cardiogenic shock. Main exposures were NLR, PLR and PCT measured within 24 h after VA-ECMO initiation. The primary endpoint was all-cause in-hospital mortality. In total, 92 patients were included into final analysis (71.7% male, age 57 ± 14 years). In-hospital mortality rate was 48.9%. Receiver operating characteristics (ROC) curve revealed an area under the curve (AUC) of 0.65 [95% confidence interval (CI) 0.53-0.76] for NLR. The AUCs of PLR and PCT were 0.47 [95%CI 0.35-0.59] and 0.54 [95%CI 0.42-0.66], respectively. Binary logistic regression showed an adjusted odds ratio of 3.32 [95%CI 1.13-9.76] for NLR, 1.0 [95%CI 0.998-1.002] for PLR and 1.02 [95%CI 0.99-1.05] for PCT. NLR is independently associated with in-hospital mortality in patients undergoing VA-ECMO. However, discriminative ability is weak. PLR and PCT seem not to be suitable for this purpose.

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Blood Platelets* / metabolism
  • Blood Platelets* / pathology
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Hospital Mortality*
  • Humans
  • Lymphocytes*
  • Male
  • Middle Aged
  • Neutrophils*
  • Platelet Count
  • Procalcitonin* / blood
  • Prognosis
  • ROC Curve
  • Retrospective Studies
  • Shock, Cardiogenic / blood
  • Shock, Cardiogenic / diagnosis
  • Shock, Cardiogenic / mortality

Substances

  • Procalcitonin
  • Biomarkers